Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...

Arcus Biosciences recently reported its third-quarter 2025 financial results, provided full-year revenue guidance of US$225 million to US$235 million, and announced an expanded collaboration as Taiho ...

Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...

This content has been selected, created and edited by the Finextra editorial team based upon its relevance and interest to our community. Tapi says it has bought Arcus's utility payments, mobile ...

EDITOR'S NOTE: This story has been updated to reflect a new opening date for Harpoon's new Manchester location. The new opening date will now be Friday, June 20. The fermentation tank outside the new ...

Wealth management technology provider Addepar acquired Arcus, a small tech startup that specializes in building out AI workflows, this week. While terms of the deal were not disclosed, Arcus’s ...

Arcus Biosciences (NYSE:RCUS) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Arcus Biosciences ...

Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board ...

Arcus Biosciences shares fell 13.9% after announcing a $150 million stock offering to fund ongoing trials for its cancer drug casdatifan. Gilead’s option to acquire casdatifan has expired, and new ...

Hauling in the big one takes patience and nerves of steel. That’s according to Capt. Niko Chaprales, one of the stars of the new reality series "Harpoon Hunters," about those who venture out into the ...